Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Prog Neurobiol. 2015 Apr 6;130:29–70. doi: 10.1016/j.pneurobio.2015.03.005

Table 3.

Intra-VP injections of dopamine and dopamine agonists produced oral dyskinesia that is comparable to that seen with intraperitoneal amphetamine.

Treatment (intra-VP, μg/0.5μl/side) Dyskinesia Score
Vehicle 9±2.0
Amphetamine 1mg/kg ip 24±5.8**
Dopamine (10) 49±11.4**
Quinpirole (13.5)# 19±3.5**
SKF82958 (21.7)# 34±9.8**
SCH23390 0.1mg/kg ip + SKF82958 (21.7)# 7±3.3
SCH23390 (0.1) + SKF82958 (21.7)# 16±4.4

An oral dyskinesia count was assigned if the animal engaged in any one of the following: chewing, teeth-grinding, licking/tongue protrusions or yawing. The oral behaviors were quantified for one min, every five min, for a total of 13 assessment periods. Intra-VP injections are described in Table 1 legend. Intraperitoneal (ip) amphetamine served as the positive control.

#

equal molar to 10 μg dopamine. ANOVA with post doc Dunnets

* P<0.05

**

P<0.001, vs. intra-VP Vehicle. Quinpirole, D2 receptor family agonist; SKF82958, D1 receptor family agonist; SCH23390, D1 receptor family antagonist. SCH23390 ip was given 30 min prior to intra-VP SKF82958 injection. Intra-VP SCH23390 immediately preceded intra-VP SKF82958. Data from Dr. Napier.